Evidence map›Paper›PMID 41683416›Full record

ArticleMolecules (Basel, Switzerland)2026

Synthesis, Antimicrobial Activity and Cytotoxicity of Novel (Piperidin-4-yl)adamantane-1-carboxylate

Kaldybay D Praliyev, Gulmira S Akhmetova, Ulzhalgas B Issayeva, Samir A Ross, Manas T Omyrzakov, Ilya S Korotetskiy, Ardak B Jumagaziyeva, Aigul E Malmakova, Tulegen M Seilkhanov, Ubaidilla M Datkhayev and 4 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kaldybay D PraliyevLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences JSC, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.ORCID 0000-0003-0381-7481
Gulmira S AkhmetovaLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences JSC, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.ORCID 0000-0002-9074-1464
Ulzhalgas B IssayevaLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences JSC, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.ORCID 0000-0001-6976-6096
Samir A RossNational Center for Natural Products Research, School of Pharmacy, The University of Mississippi, Oxford, MS 38677, USA.ORCID 0000-0002-3807-1299
Manas T OmyrzakovSchool of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0002-2665-178X
Ilya S KorotetskiyScientific Center for Anti-Infectious Drugs JSC, Almaty 050060, Kazakhstan.ORCID 0000-0002-0397-7840
Ardak B JumagaziyevaScientific Center for Anti-Infectious Drugs JSC, Almaty 050060, Kazakhstan.ORCID 0000-0002-8610-7321
Aigul E MalmakovaLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences JSC, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.ORCID 0000-0001-9996-9476
Tulegen M SeilkhanovThe Laboratory of Engineering Profile of NMR Spectroscopy, Sh. Ualikhanov Kokshetau State University, Kokshetau 020000, Kazakhstan.ORCID 0000-0003-0079-4755
Ubaidilla M DatkhayevSchool of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0002-2322-220X
Lyudmila N IvanovaScientific Center for Anti-Infectious Drugs JSC, Almaty 050060, Kazakhstan.ORCID 0000-0002-7194-0556
Zhanar A IskakbayevaScientific Center for Anti-Infectious Drugs JSC, Almaty 050060, Kazakhstan.ORCID 0000-0001-7428-0074
Olzhas T SeilkhanovThe Laboratory of Engineering Profile of NMR Spectroscopy, Sh. Ualikhanov Kokshetau State University, Kokshetau 020000, Kazakhstan.ORCID 0000-0002-2322-8863
Natalya V ZubenkoScientific Center for Anti-Infectious Drugs JSC, Almaty 050060, Kazakhstan.ORCID 0000-0001-6436-803X

Funding

Research funding for this project was provided by the Committee of Science of the Ministry of Science and Higher Education of the Republic of Kazakhstan AP26198287
6 · The paper itself

Abstract

The cyclic adamantane framework possesses unique properties such as bulkiness, symmetry, and high lipophilicity. Research aimed at discovering new pharmaceutical agents within the adamantane series continues. In the present work, a targeted modification was carried out to combine two pharmacophore fragments-adamantane and piperidine-within a single molecule. Based on a series of

Indexed as

AdamantaneAnti-Bacterial AgentsAntifungal AgentsAnti-Infective AgentsPiperidinesCandida albicansHumansMicrobial Sensitivity TestsMolecular StructureStaphylococcus aureusStructure-Activity RelationshipAdamantaneAnti-Bacterial AgentsAntifungal AgentsAnti-Infective AgentsPiperidinesadamantancarboxylatesantifungal activityantimicrobial activitycytotoxicitypiperidines

Identifiers

PMID41683416
PMCPMC12899892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.